Why the study?
Does a multimarker strategy using Troponin, CRP, and BNP improve risk stratification for major cardiac events in patients with Non-ST Elevation Acute Coronary Syndromes?
Does a multimarker strategy using Troponin, CRP, and BNP improve risk stratification for major cardiac events in patients with Non-ST Elevation Acute Coronary Syndromes?
Combining Troponin, CRP, and BNP into a simple multimarker strategy provides effective short- and long-term risk stratification for patients with NSTE-ACS.
May aid NSTE-ACS risk stratification; leaves open whether it alters management or outcomes.
Troponin, CRP, and BNP each provide unique prognostic information in patients with ACS. A simple multimarker strategy that categorizes patients based on the number of elevated biomarkers at presentation allows risk stratification over a broad range of short- and long-term major cardiac events.
No takes yet. Share an insight, caveat, or question.
Sabatine et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: